A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
NCT07103369
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
SM17 for injection
OTHER:
SM17 placebo for injection
Sponsor
SinoMab BioScience Ltd